The Role of m(6)A/m-RNA Methylation in Stress Response Regulation

Mareen Engel, Max Planck Institute of Psychiatry
Carola Eggert, Max Planck Institute of Psychiatry
Paul M. Kaplick, Max Planck Institute of Psychiatry
Matthias Eder, Max Planck Institute of Psychiatry
Simone Röh, Max Planck Institute of Psychiatry
Lisa Tietze, Max Planck Institute of Psychiatry
Christian Namendorf, Max Planck Institute of Psychiatry
Janine Arloth, Max Planck Institute of Psychiatry
Peter Weber, Max Planck Institute of Psychiatry
Monika Rex-Haffner, Max Planck Institute of Psychiatry

Only first 10 authors above; see publication for full author list.

Journal Title: Neuron
Volume: Volume 99, Number 2
Publisher: Elsevier (Cell Press) | 2018-07-25, Pages 389-+
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1016/j.neuron.2018.07.009
Permanent URL: https://pid.emory.edu/ark:/25593/t6jj3

Final published version: http://dx.doi.org/10.1016/j.neuron.2018.07.009

Copyright information:
© 2018 The Author(s)
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed January 17, 2019 7:12 PM EST
The Role of m$^6$A/m-RNA Methylation in Stress Response Regulation

Graphical Abstract

Highlights

- m$^6$A/m mRNA methylation in the adult mouse brain is regulated by stress
- m$^6$A/m mRNA regulation is brain region, time, and gene specific
- Mettl3 and Fto cKO alter m$^6$A/m, fear memory, expression, and synaptic plasticity
- The m$^6$A/m glucocorticoid response is impaired in major depressive disorder patients

Authors
Mareen Engel, Carola Eggert, Paul M. Kaplick, ..., Jan M. Deussing, Elisabeth B. Binder, Alon Chen

Correspondence
alon_chen@psych.mpg.de

In Brief
Engel et al. demonstrate a region- and time-dependent role of brain m$^6$A/m methylation in stress-response regulation. Manipulating m$^6$A/m alters fear memory, transcriptome response, and synaptic plasticity. Altered m$^6$A/m dynamics in depressed patients suggest importance of m$^6$A/m modifications for stress-related psychiatric disorders.
The Role of m\(^6\)A/m-RNA Methylation in Stress Response Regulation


1Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, Munich 80804, Germany
2Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich 80804, Germany
3Clinical Laboratory, Max Planck Institute of Psychiatry, Munich 80804, Germany
4Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
5Bioinformatics Unit, Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 76100, Israel
6Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
7Department of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel
8Lead Contact
*Correspondence: alon.chen@psych.mpg.de
https://doi.org/10.1016/j.neuron.2018.07.009

SUMMARY

N\(^6\)-methyladenosine (m\(^6\)A) and N\(^6,2\)′-O-dimethyladenosine (m\(^6\)Am) are abundant mRNA modifications that regulate transcript processing and translation. The role of both, here termed m\(^6\)A/m, in the stress response in the adult brain in vivo is currently unknown. Here, we provide a detailed analysis of the stress epitranscriptome using m\(^6\)A/m-seq, global and gene-specific m\(^6\)A/m measurements. We show that stress exposure and glucocorticoids region and time specifically alter m\(^6\)A/m and its regulatory network. We demonstrate that deletion of the methyltransferase Mettl3 or the demethylase Fto in adult neurons alters the m\(^6\)A/m epitranscriptome, increases fear memory, and changes the transcriptome response to fear and synaptic plasticity. Moreover, we report that regulation of m\(^6\)A/m is impaired in major depressive disorder patients following glucocorticoid stimulation. Our findings indicate that brain m\(^6\)A/m represents a novel layer of complexity in gene expression regulation after stress and that dysregulation of the m\(^6\)A/m response may contribute to the pathophysiology of stress-related psychiatric disorders.

INTRODUCTION

Regulation of gene expression in response to stressful stimuli under healthy or pathological conditions involves epigenetic mechanisms such as DNA methylation and chromatin modifications (de Kloet et al., 2005; McEwen et al., 2015). Elucidating the underlying molecular processes that regulate the fine-tuned transcriptional response to stress is essential for understanding stress vulnerability and the development of stress-related psychiatric disorders such as depression and anxiety.

In analogy to DNA modifications, a diverse set of covalent modifications is present on RNA nucleotides encoding the epitranscriptome, post-transcriptionally shaping gene expression via regulation of RNA stability, translation, and non-coding transcript function (Zhao et al., 2017). The role of this newly emerging layer of gene expression control in the central stress response and behavior is not fully understood yet (Engel and Chen, 2018). RNA modifications, next to epigenetic mechanisms, likely represent a yet undescribed level of transcriptional regulation highly relevant for psychiatry.

N\(^6\)-methyladenosine (m\(^6\)A) is the most abundant internal mRNA modification, which is present transcriptome-wide in at least one-fourth of all RNAs, typically located in a consensus motif (DRACH/GGACU), and enriched near stop codons and in 5′ UTRs (Dominissini et al., 2012; Linder et al., 2015; Meyer et al., 2012). Recent studies have identified mammalian m\(^6\)A to be dynamically regulated, controlling stem cell proliferation and differentiation (Klungland et al., 2016), cellular heat-shock response (Zhou et al., 2015), DNA damage response (Xiang et al., 2017), and tumorigenesis (Cui et al., 2017). Brain RNA methylation is comparably high and increases during development (Meyer et al., 2012).

m\(^6\)A is deposited co-transcriptionally (Ke et al., 2017; Slobodin et al., 2017) by a methyltransferase complex consisting of METTL3, METTL14 (Liu et al., 2014), WTAP (Ping et al., 2014), KIAA1429 (VIR; Schwartz et al., 2014), and enriched near stop codons and in 3′ UTRs (Maurer et al., 2017). In contrast, it can be removed by the demethylases FTO (Jia et al., 2011; Mauer et al., 2017) and ALKBH5 (Zheng et al., 2013). FTO further catalyzes the demethylation of N\(^6,2\)′-O-dimethyladenosine (m\(^6\)Am) with an in vitro preference for this substrate (Mauer et al., 2017). m\(^6\)Am is found at the first nucleotide adjacent to the 7-methylguanosine cap, promoting transcript stability (Mauer et al., 2017). Fto has been associated with memory consolidation (Walters et al., 2017; Widagdo et al., 2016) and was implicated in regulation of dopaminergic brain
networks (Hess et al., 2013). The most commonly used m⁶A/m antibody, used also in most experiments presented here, co-detects m⁶A and m⁶Am (Linder et al., 2015), potentially preventing clear discrimination between them. Therefore, data will be treated as potentially containing both and called m⁶A/m unless otherwise stated.

In general, m⁶A/m-regulating enzymes may be expressed at different levels in different cell types and have distinct intracellular distributions and binding motifs and thus potentially affect different subsets of target RNAs. Cellular consequences of m⁶A/m modifications depend on the binding of m⁶A/m-reader proteins (such as YTH and HNRNP proteins) and include RNA maturation, splicing, alternative polyadenylation, RNA decay, and both promotion and inhibition of protein translation (reviewed in Peer et al., 2017, Roundtree et al., 2017).

In this study, we aimed to elucidate the role of m⁶A/m in the context of the brain’s stress response. We delineated the effects of acute stress on m⁶A/m using global m⁶A/m measurements, m⁶A/m sequencing (m⁶A/m-seq), and absolute quantification of transcript-specific methylation levels. In addition, we explored the functional significance of m⁶A/m in the adult brain by examining conditional knockout (cKO) mice for Mettl3 and Fto. Finally, we investigated m⁶A/m regulation in blood samples of mice and humans to determine its potential as a peripheral indicator of the central response to stress and stress-linked psychiatric disorders.

RESULTS

The Stress-Induced m⁶A/m Epitranscriptome

To test whether acute stress alters m⁶A/m, we performed m⁶A/m-seq (RNA-seq after immunoprecipitation) on mouse cortex poly(A)-RNA 4 hr following 15 min of acute restraint stress exposure (n = 6–7). Using more specific areas, and thus lower amounts of input material, was not sufficient for consistent, quantifiable poly(A)-m⁶A/m-seq. The peaks enriched in the m⁶A/m-RIP (RNA immunoprecipitation)-seq over the input-RNA-seq in the two different conditions were very similar (Figures S1A and S1B). We analyzed differential methylation across an m⁶A/m consensus peak set with 14,656 high-confidence m⁶A/m peaks (supported by either 2/3 samples per group or 1/2 of all samples and additional abundance filters) mapping to 7,982 genes (Figure 1A; Table S1). Thus, around half of the expressed genes in the mouse cortex are m⁶A/m methylated with each around 2 peaks per gene (Figure 1A). m⁶A/m peaks overlapped majorly with previously reported m⁶A/m peaks (85% overlap with RMBase 2; Xuan et al., 2018), preferentially located to the 5’ UTR and around the stop codon (Figure 1B), and contained the m⁶A consensus motif with the top motif being a centrally enriched GGACWB (Figure 1C). m⁶A/m methylation in the cortex is overrepresented in genes involved in synaptic and neuronal regulation (Figure S1C).

Only 25 m⁶A/m peaks (in 20 different genes) and 13 genes were found to be significantly regulated 4 hr after stress, but all with very low fold changes (at absolute log2 fold change > 0.2 for m⁶A, > 0.1 for RNA, and Q < 0.1; Figures 1A and S1D–S1G; two examples including validation by m⁶A/RIP-qPCR are shown in Figure 1D), potentially reflecting the cellular heterogeneity of the input material used diluting the cell-specific effects of stress. RNAs and m⁶A/m peaks significantly regulated by stress showed only low overlap (three genes) and no prominent correlation of m⁶A/m and gene expression regulation by stress (Figure S1E).

To investigate if m⁶A and m⁶Am may have different effects after stress, we in silico dissected m⁶A and m⁶Am peaks based on the assumption that m⁶Am occurred at the first nucleotide after the transcription start site (similar to strategies employed earlier by Linder et al., 2015 and Mauer et al., 2017). We observed 1,801 putative m⁶Am peaks (12%; Figures 1E and S2A) with highest gene ontology enrichment in developmental genes and genes related to DNA and RNA rather than neuronal genes (Figure S2B) and no enrichment of a GGAC motif (data not shown). Putative m⁶Am peaks were not overrepresented in stress-regulated peaks (data not shown), and had similar stress regulation like all peaks (Figure S2C) and similar absence of correlation to stress regulation of gene expression (Figure S2C), overall not indicating a special role of m⁶Am in the stress response. Further, in order to assess potential regulation of transcript translation by stress-regulated m⁶A/m, we performed ribosome profiling on mouse cortex 4 hr after stress. Although there were several genes with regulated translation efficiency after stress (24 genes at Q < 0.1, absolute log2 fold changes > 0.5), none overlapped with stress-regulated m⁶A/m and there was also no apparent relation to stress regulation of m⁶A/m (Figure 1F). Finally, searching for potential binding factors for m⁶A/m, we analyzed the co-occurrence of the overexpressed m⁶A motif GGACWB to known binding motifs of RNA-binding proteins in the m⁶A/m-seq fragments, observing a high similarity and summit enrichment to the binding motifs of FMRP/FMR1 and FXR2, proteins crucial for translation regulation, RNA translocation, and synaptic plasticity in neurons (Figure S2D). Likewise, genes reported to be bound by mouse FMRP were also higher than likely m⁶A/m methylated (Figure S2E), suggesting that m⁶A/m methylation of neuronal RNAs may regulate protein binding critical for neuronal transport and plasticity.

Stress Regulation of m⁶A/m Is Brain Region Specific

Based on both the number of significantly stress-regulated m⁶A/m peaks and their respective fold changes in m⁶A/m-seq being very small, we reasoned that the true extent of the m⁶A/m stress response may only be revealed when investigating more defined brain regions. Therefore, we measured the time course of RNA methylation changes in two regions highly involved in stress response regulation: the medial prefrontal cortex (PFC) and the basolateral and central amygdala (AMY; Figure 2A). We found that global m⁶A/m was regulated in total RNA in a region-dependent manner with RNA methylation decreased in the PFC and increased in the AMY (Figure 2B). The same regulation was observed when only m⁶A was measured in mRNA using liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Figure 2C), arguing for m⁶A as the main driver of the observed effects. Examining changes of the m⁶A/m machinery related to these global changes, we measured gene expression levels of m⁶A/m enzymes and binding proteins. We found the demethylases Fto and Alkbh5 to be differentially regulated in a region-specific manner, facilitating the effects
Figure 1. Mapping the Transcriptome-wide m^6^A/m Landscape after Acute Restraint Stress in the Mouse Cortex Using m^6^A/m-Seq

(A) Approximately half of the genes expressed in the mouse cortex are m^6^A/m methylated, but only a minor fraction is regulated by acute stress on cortex-wide level. m^6^A/m-seq of mouse cortex poly(A^-)-RNA basal or 4 hr after 15 min restraint stress; n = 6–7, each pooled from 3 mice. Stress-regulated m^6^A/m peaks, Q < 0.1 and absolute log2 fold change > 0.2; stress-regulated mRNAs ( = differential expressed genes), Q < 0.1 and absolute log2 fold change > 0.1.

(B) m^6^A/m peaks are enriched at the 5’ UTR and the stop codon with similar distribution of all and stress-regulated peaks (peak distribution mapped along mRNA relative position).

(C) GGACWB is the most abundant motif detected in m^6^A/m peaks and enriched at peak summits. Top enriched sequence motif and its position across the detected m^6^A/m peaks.

(D) Two examples of stress-regulated m^6^A/m peaks and replication of their quantitative regulation by m^6^A/m-RNA immunoprecipitation (RIP)-qPCR in an unrelated cohort of animals. Left panel per gene: averaged sequence tracks and peaks; arrows indicate quantitatively regulated peaks. Right panel per gene: differential methylation was validated in a separate cohort of mice using full-length m^6^A/m-RIP-qPCR, including an intermediate time point (1 hr). n = 7, mean ± SEM; asterisks [*] depict omnibus Tukey post hoc tests to basal p < 0.05 after FDR-corrected one-way ANOVA.

(E) Bioinformatic dissection of m^6^Am peaks based on their position at the transcription start site, observing 1,801 putative m^6^Am sites. m^6^Am peaks do not show a preference for stress-regulated peaks.

(F) Regulation of translation efficiency (TE assessed by ribosome profiling) by stress does not correlate well or overlap with regulation of m^6^A/m methylation. n = 6 for ribosome profiling; n = 6–7 for m^6^A/m profiling. Shown are fold changes upon stress using only genes abundantly detected in ribosome profiling sequencing with significance determined by Q < 0.1 and absolute log2 fold change > 0.2.

See also Figures S1 and S2 and Table S1.
observed on global methylation, in most cases preceding the effect observed on global m⁶A/m (Figure 2D). Furthermore, Mettl3 was downregulated upon stress exposure tissue independently (Figure 2D) and Wtap was regulated isofrom specifically only in the AMY (Figure S3A). The m⁶A/m reader Ythdc1 was regulated in a region-specific manner (Figure 2D), whereas the other known enzymes and readers were not differentially expressed (Figure S3A).

Notably, intraperitoneal (i.p.) injection of the endogenous glucocorticoid corticosterone, but not the glucocorticoid receptor agonist dexamethasone, changed global m⁶A/m (Figure 2E), as well as Fto and Alkbh5 expression (Figure S3B), similarly to acute stress (Figure 2D), demonstrating that the stress effect may be mediated by endogenous glucocorticoids (GCs). Supporting this idea, we found that the majority of m⁶A/m enzyme and reader genes contain several GC response elements in their 5' upstream region, likewise pointing at expression regulation of those genes via GCs (Figure S3C).

Stress Regulation of m⁶A/m Is Gene Specific
m⁶A/m-seq not only requires large amounts of input material but also does not quantify absolute transcript methylation. Therefore, we performed m⁶A/m-RIP followed by qPCR to assess absolute levels of candidate transcript methylation in narrowly defined brain areas, before and after stressful challenge. For calibration of the assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal assay and normalization of immunoprecipitation efficiency in experiments, we designed and used an m⁶A/m methylated internal ass
Figure 3. Absolute Regulation of m^6^A/m Methylation Is Site Specific

(A) A synthetic RNA oligonucleotide with three internal m^6^A/m sites was used for validation and internal normalization of the m^6^A/m-RIP-qPCR. See also Figure S4.

(B) m^6^A/m-RIP-qPCR detects the methylated spike-in oligonucleotide in a linear fashion without impairing precipitation efficiency for endogenous transcripts in the concentration range used for experiments. Methylated spike-in oligo was added to unfragmented total RNA and precipitated with anti-m^6^A/m antibody (m^6^A/m-RIP) or rabbit IgG (IgG NC). n = 3 technical replicates, normalized expression to 1 fmol input control. Mean ± SEM.

(C) m^6^A/m-RIP-qPCR accurately quantifies differential methylation of the spike-in oligo. Spike-in oligo (1 fmol) mixed from fully methylated and fully unmethylated m^6^A/m stress effect

(D) Absolute full-length m^6^A/m levels of stress-related and synaptic plasticity-related transcripts are differentially regulated in the PFC and AMY of stress-related candidates and synaptic-plasticity-related candidate transcripts after stress. See also Figure S4. n = 8, mean ± SEM. Significant effects observed in FDR-corrected two-way MANOVA (p < 0.05, n^2 > 0.01) are coded in the rows “m^6^A/m stress effect” and “RNA stress effect.” Orange/blue arrows, PFC/AMY-specific stress effect (interaction effect two-way ANOVA, one-way follow-up significant in respective tissue); black arrow, stress main effect; equals sign, no interaction or stress main effect in two-way ANOVA. See also Table S2.

(E) The majority of transcripts measured are expressed or regulated in a region-specific manner, Percent of transcripts with significant interaction or main effect in FDR-corrected 2 x 2 MANOVA.

(F) Stress regulation of m^6^A/m negatively correlates with changes in RNA levels, log2 fold changes of m^6^A/m and RNA after stress to basal time points, n = 44 per group; black line, linear model ± 95% CI. For generalized linear models (GLMs), see Table S2.

(G) General patterns of m^6^A/m changes vary in extent and direction depending on brain region and time point. Density plots of data depicted in (D); 1 test.

(H) The m^6^A/m change at the 1 hr time point correlates with the m^6^A/m change at 4 hr in the PFC, but not AMY, indicating that in the PFC, m^6^A/m change 1 hr after stress is a proxy for later change. Orange line, linear model for PFC only ± 95% CI. For GLMs, see Table S2.

See also Figure S4.

brain’s stress response and, given the enrichment of neuronal plasticity and morphogenesis-related terms in the m^6^A/m-seq, synaptic plasticity-related transcripts (Figures 3D and S4C). Regulation of m^6^A/m by stress (26/44 transcripts) was observed more often than regulation of RNA (16/44 transcripts, with 12 overlapping) in the transcripts tested. Notably, the majority of chosen candidates were either regulated or expressed in a region-specific manner, emphasizing the importance of assessing...
RNA methylation in defined brain areas (Figure 3E). Interestingly, in contrast to the m^6^A/m-seq, absolute transcript methylation levels m^6^A/m and RNA fold changes negatively correlated, arguing for increased m^6^A/m levels correlating with mRNA decay as previously shown in vitro (Figure 3F; Table S2; with no influence of region and time point). In detail, both PFC and AMY exhibited differential response at 1 and 4 hr with opposite directions, paralleling the regulation observed in global m^6^A/m in the respective regions above (Figure 2B). Overall, 4 hr fold changes had higher effect sizes compared to 1 hr fold changes (Figure 3G). Fold changes at the 1 hr time point correlated with those at 4 hr for the same gene in the PFC, but not in the AMY, indicating that in the PFC 1 hr m^6^A/m may be an intermediate state of 4 hr regulation with fold changes of regulated m^6^A/m increasing with time. In contrast, in the AMY for the candidate genes investigated, m^6^A/m regulation after 1 and 4 hr was more independent (Figure 3H).

**Epitranscriptomic Changes in Mice with Conditional Deletion of Mettl3 or Fto from Adult Neurons**

Since the expression of the m^6^A methyltransferase Mettl3 and the m^6^A/m demethylase Fto was affected by acute stress, we generated cKO mouse models lacking these genes specifically in adult excitatory neurons employing Mettl3 or Fto flox/flox mice bred to Cre-driver lines. First, to measure the regulation of the epitranscriptome in these mice, we used the Camk2a-Cre driver, which induces gene deletion in excitatory neurons of neocortex and hippocampus (Minichiello et al., 1999) starting 2–3 weeks postnatal (Refojo et al., 2011), leading to broad reductions of both Mettl3 and Fto mRNA and METTL3 and FTO protein in the adult brain (Figures 4A, 4B, and S5A). Whereas global m^6^A measured by LC-MS/MS was decreased in cortical mRNA of Mettl3 cKOs (compared to their respective Mettl3 wild-type [WT] littersmates), conditional deletion of Fto did not alter m^6^A (Figures 4C and S5B). However, using an LC-MS/MS mRNA preparation including a cap-digest similar to previously published protocols (Mauer et al., 2017), we found that m^6^Am is increased in Fto cKO (Figure 4D; significantly increased both relative to Am or A with no change in Am; data not shown). These data confirm FTO primarily targeting m^6^Am in the adult brain in vivo (Mauer et al., 2017). m^6^Am and Am were below quantification threshold in all of the Mettl3 cKOs, but not Mettl3 WT animals (data not shown), potentially indicating an effect of METTL3 depletion on those nucleosides that should be confirmed with a more sensitive method. Absolute abundancies measured by LC-MS/MS in cortical mRNA were 0.304% for m^6^A/A, 0.022% for m^6^Am/A, and 0.071% for m^6^Am/m^6^A. m^6^Am could not be detected in sufficient amounts for quantification in any of the samples (data not shown).

We next profiled m^6^A/m in Mettl3 cKO and Fto cKO mice using m^6^A/m-seq on cortical poly(A)-RNA. Overall, m^6^A/m peaks detected in the single groups were still fairly similar (Figures S5C and SSD), with 80% overlap with the m^6^Am dataset generated after acute stress (Figures S5D and SSE; mainly lacking 5’ UTR peaks potentially due to use of a different antibody lot). Quantitative analysis of consensus peaks revealed majorly altered epitranscriptomes in both mouse lines (Figures 4E and 4G; Table S3), with much higher numbers of consensus m^6^A/m peaks quantitatively altered in Mettl3 cKO compared to WT (1,266) compared to Fto cKO compared to WT (78; both Q < 0.1 and absolute log2 fold change > 0.5), and only a small number shared differentially methylated sites (Figure S5F). Although several RNAs are differentially expressed in Mettl3 cKOs or Fto cKOs, they only minorly overlapped with the regulated m^6^A/m peaks in the respective line (Figure S5F). Peaks differentially methylated in Mettl3 cKOs and Fto cKOs both showed higher enrichment at the 5’ UTR compared to all measured peaks (Figure 4F). Interestingly, Fto cKO differential peaks do not only localize to the 5’ UTR, as would be expected from m^6^Am sites only, but also to internal sites, arguing for Fto deletion also affecting internal m^6^A sites. Functionally, while m^6^A/m peaks are enriched in genes related to (mature) synapse and neuronal function, Mettl3 differential m^6^A peaks are more abundant in genes with neuronal and tissue-developmental functions (Figure S5G).

**Stress-Coping Behavior Is Altered in Mice Deficient in Mettl3 or Fto**

To assess behavioral and electrophysiological consequences of Mettl3 and Fto deletion in vivo, we created cKO mice with a more defined gene deletion by breeding Mettl3 or Fto flox/flox mice to Nex-CreERT2 mice in which additionally the gene deletion can be timely controlled by tamoxifen (Agarwal et al., 2012; Mettl3 cKO and Fto cKO). Upon induction in young adults, Mettl3 and Fto mRNA were depleted from both dorsal and ventral parts of the hippocampus, specifically in CA1 and CA3, but not in the dentate gyrus (Figure 5A). METTL3 and FTO proteins were significantly reduced in dCA1/dCA3 in Mettl3 cKO and Fto cKO mice, respectively (Figures 5B and 5A). Nex-CreERT2-induced recombination is further known to occur in small populations of principal neurons in the cortex (Agarwal et al., 2012). Depletion of either gene did not result in compensatory changes of gene expression of other genes involved in m^6^A/m metabolism (Figure S6B) but altered transcriptome profiles as observed by mRNA-seq of CA1 and CA3 tissue (Figure 5C). Interestingly, in non-stressed basal animals, we observed a larger number of differentially expressed genes in Mettl3 cKOs compared to Fto cKOs (Figures 5B and 5C; Mettl3 cKOs, 84 differentially expressed genes; Fto cKOs, 15 differentially expressed genes with Q < 0.1 and an absolute fold change above log2 = 0.5; Table S4), with no apparent preference for up- or downregulation. Although there was only small overlap of differentially expressed genes between the two lines, 104 genes were differentially expressed in a knockout-specific pattern (Figure 5C), including genes regulating neuronal activity and synaptic function (examples shown Figure 5D).

Neither Mettl3 cKO nor Fto cKO mice showed altered anxiety-like behavior or locomotion (Figure 7A), but we observed significant changes in spontaneous digging behavior (Figure 7A). Both knockout mice exhibited increased cued fear memory long-term maintained during memory extinction (Figure 6A) as well as contextual fear memory in Fto cKO mice (Figure 6A), but no differences in non-fear-related memory or short-term working memory (Figure 6A). Next, we investigated the transcriptional response patterns 24 hr after fear conditioning stress; thus, at the time point we observed the altered memory, comparing
fear conditioned animals ("FC") to control animals that experienced the same handling but no foot shock ("Box"). For both Mettl3 cKOs and Fto cKOs, we observed a large number of genes differentially expressed after fear conditioning in a genotype-dependent manner, implying a widely altered transcriptional response pattern after stress in animals with disturbed m6A/m system (Figure 6B) involving genes crucial for neuronal systems like neurotransmitter receptors and transporters as well as transcription factors (Figure 6C). Thereby, significant gene expression regulation was more extended in fear-conditioned animals compared to non-fear-conditioned animals (Figure S7B; Table S4). In contrast to basal animals, Fto cKOs

Figure 4. Depletion of METTL3 and FTO in Adult Excitatory Neurons Using the Camk2a-Cre Driver Changes the Cortex Epitranscriptome

(A) Mettl3 and Fto mRNA are depleted from the neocortex and hippocampus in Mettl3 cKO and Fto cKO mice, respectively. In situ hybridization, n = 3, representative shown. WT, wild-type; cKO, conditional.

(B) METTL3 and FTO proteins are significantly depleted in Mettl3 cKO and Fto cKO mice, respectively. Western blot of PFC protein, optical density normalized from digitally acquired image signal normalized to ACTB protein. n = 4–5, mean ± SEM. *p < 0.05, t test. For full blots, see Figure S5.

(C) Global mRNA m6A is decreased in Mettl3 cKO mice, but not in Fto cKO mice, when measured with LC-MS/MS. n = 5, mean ± SEM, m6A-specific measurement. Two-way ANOVA interaction effect F(1, 19) = 106.269, p < 0.001. *p < 0.05, omnibus Tukey post hoc tests to respective WT. See also Figure S5.

(D) Global mRNA m6Am is increased in Fto cKO mice when measured with LC-MS/MS. n = 5, mean ± SEM, m6Am-specific measurement. Data are shown relative to Am, which is not altered in Fto cKO mice. *p < 0.05, t test. For LC-MS/MS traces, see Figure S5.

(E) The m6A/m epitranscriptome is widely altered in Mettl3 cKO and Fto cKO mice. m6A/m-seq on mouse cortex poly(A)-RNA of WT and cKO animals reported 1,266 and 78 significantly different methylated m6A/m peaks in Mettl3 cKO and in Fto cKO compared to WT, respectively, with 14 shared peaks. n = 3–5, each pooled from 3 mice. WT of both lines were grouped together as we observed no major regulation between them. Shown are log2 fold changes of methylation in cKO relative to WT mice using 10,109 high-confidence consensus m6A/m peaks detected across all groups, mapping to 6,056 unique genes. Significantly regulated m6A/m peaks are Q < 0.1 and absolute log2 fold change > 0.5.

(F) m6A/m peaks are enriched at the stop codon with a less prominent enrichment at the 5’ UTR, as observed in Figure 1. Differentially methylated peaks in both Mettl3 cKO and Fto cKO mice show an increased preference for 5’ UTR position with a decreased preference for CDS peaks in Mettl3 cKO differential peaks. Peak distribution mapped along mRNA relative position.

(G) Two examples m6A/m peaks regulated only in Mettl3 cKO or in both Mettl3 cKO and Fto cKO. Shown are averaged sequence tracks m6A/m-seq and RNA-seq per group and detected m6A/m peaks. Arrows indicate quantitatively regulated peaks (Q < 0.1, absolute log2 fold change > 0.5).

See also Figure S5 and Table S3.
Regulation of m6A/m Is Impaired in MDD Patient Blood

To evaluate the potential of blood m6A/m as a peripheral proxy of the central m6A/m stress response, we measured global m6A/m methylation levels in mouse and human blood after an acute stressful challenge and GC stimulation. Global methylation was transiently decreased in whole blood of mice after acute stress (Figure S7C), with gene expression of Mettl3 and Alkbh5 altered in accordance with the global m6A/m change and Wtap being upregulated (Figure 7A). Similarly, global m6A/m was decreased in mouse blood 4 hr after i.p. injections of both corticosterone and dexamethasone (Figure 7C). Comparably, blood from healthy human volunteers, drawn before and after intake of 1.5 mg dexamethasone, showed both reduced global m6A/m levels (Figure 7D) and changes in gene expression of the m6A/m machinery enzymes 3 hr after dexamethasone intake (Figure 7E; expression data from Arloth et al., 2015). Since dysregulation of the stress response may be an important feature of psychopathologies like major depressive disorder (MDD), we next investigated whether m6A/m regulation in response to dexamethasone differs between healthy individuals and MDD patients. In contrast to healthy subjects, downregulation of m6A/m in response to dexamethasone was observed in neither male nor female MDD patients (Figure 7F; significant within-subject diagnosis x dexamethasone genotype interaction-dependent matter. Normalized counts relative to Mettl3 WT. n = 5. See also Figures S6 and S7 and Table S4.

Figure 5. Deletion of Mettl3 or Fto in Adult Excitatory Neurons of the Hippocampus CA1 and CA3 via a Nex-CreERT2 Driver Line and Knockout Induction in Adult Animals via Tamoxifen Administration Alters Gene Expression in Animals

(A) Mettl3 and Fto mRNA are depleted from the dorsal (d) and ventral (v) hippocampus CA1 and CA3 in Mettl3 cKO (blue) and Fto cKO (pink) mice, respectively. WT, wild-type; cKO, conditional knockout; DG, dentate gyrus. In situ hybridization; expression was quantified from digitalized films in arbitrary units (AU); mean ± SEM, n = 4 for Mettl3 WT and cKO, n = 11–14 for Fto WT and cKO, signal averaged across both hemispheres; *p < 0.05, t test. For full blots, see Figure S6.

(B) METTL3 and FTO proteins are significantly depleted in Mettl3 cKO and Fto cKO mice, respectively. Protein was isolated from dissected dCA1/dCA3 and measured by western blot normalized to ACTB protein. n = 3–4, optical density normalized from digitally acquired images, mean ± SEM. *p < 0.05, t test. For

C

mRNA log2 FC

mRNA abundance (normalized counts)

D

mRNA level

Figure 6B and S7B; Table S4), implying that Fto is crucial for the regulation of the fear response despite minor basal changes in gene expression.

Consequently, investigating the effects of Fto and Mettl3 depletion on electrophysiological correlates of network plasticity and brain function, we found that CA1 long-term potentiation was impaired in Fto cKO, but not in Mettl3 cKO, mice (Figure 6D), with no effect on paired-pulse facilitation (Figure 6D) or basal neurotransmission (Figure S7C).

showed more genotype-dependent expression changes after the stressful fear conditioning event than Mettl3 cKOs (Figures 6B and S7B; Table S4), implying that Fto is crucial for the regulation of the fear response despite minor basal changes in gene expression.

Consequently, investigating the effects of Fto and Mettl3 deletion on electrophysiological correlates of network plasticity and brain function, we found that CA1 long-term potentiation was impaired in Fto cKO, but not in Mettl3 cKO, mice (Figure 6D), with no effect on paired-pulse facilitation (Figure 6D) or basal neurotransmission (Figure S7C).

**Regulation of m6A/m Is Impaired in MDD Patient Blood**

To evaluate the potential of blood m6A/m as a peripheral proxy of the central m6A/m stress response, we measured global m6A/m methylation levels in mouse and human blood after an acute stressful challenge and GC stimulation. Global methylation was transiently decreased in whole blood of mice after acute stress (Figure 7A), with gene expression of Mettl3 and Alkbh5 altered in accordance with the global m6A/m change and Wtap being upregulated (Figure 7B). Similarly, global m6A/m was decreased in mouse blood 4 hr after i.p. injections of both corticosterone and dexamethasone (Figure 7C). Comparably, blood from healthy human volunteers, drawn before and after intake of 1.5 mg dexamethasone, showed both reduced global m6A/m levels (Figure 7D) and changes in gene expression of the m6A/m machinery enzymes 3 hr after dexamethasone intake (Figure 7E; expression data from Arloth et al., 2015).

Since dysregulation of the stress response may be an important feature of psychopathologies like major depressive disorder (MDD), we next investigated whether m6A/m regulation in response to dexamethasone differs between healthy individuals and MDD patients. In contrast to healthy subjects, downregulation of m6A/m in response to dexamethasone was observed in neither male nor female MDD patients (Figure 7F; significant within-subject diagnosis x dexamethasone genotype interaction-dependent matter. Normalized counts relative to Mettl3 WT. n = 5. See also Figures S6 and S7 and Table S4.

**Figure 5. Deletion of Mettl3 or Fto in Adult Excitatory Neurons of the Hippocampus CA1 and CA3 via a Nex-CreERT2 Driver Line and Knockout Induction in Adult Animals via Tamoxifen Administration Alters Gene Expression in Animals**

(A) Mettl3 and Fto mRNA are depleted from the dorsal (d) and ventral (v) hippocampus CA1 and CA3 in Mettl3 cKO (blue) and Fto cKO (pink) mice, respectively. WT, wild-type; cKO, conditional knockout; DG, dentate gyrus. In situ hybridization; expression was quantified from digitalized films in arbitrary units (AU); mean ± SEM, n = 4 for Mettl3 WT and cKO, n = 11–14 for Fto WT and cKO, signal averaged across both hemispheres; *p < 0.05, t test. For full blots, see Figure S6.

(B) METTL3 and FTO proteins are significantly depleted in Mettl3 cKO and Fto cKO mice, respectively. Protein was isolated from dissected dCA1/dCA3 and measured by western blot normalized to ACTB protein. n = 3–4, optical density normalized from digitally acquired images, mean ± SEM. *p < 0.05, t test. For
effect only). Bootstrapping statistics performed for the reported significant subject diagnosis × dexamethasone treatment effect reported the 95% confidence interval of the F-statistic based on 10,000 bootstraps as [5.26, 33.91] and thus well above the critical $F_{\text{crit}}(1, 96) = 3.94$, supporting that the chosen sample size was sufficient for detecting the within-subject diagnosis-dependent dexamethasone effect reported.

To exclude any influence by changes in blood cell composition rather than m6A/m levels, we compared estimates of the fractions of different blood cell types derived from the residuals of

![Figure 6. Animals with Adult Excitatory Neuron-Specific Depletion of Mettl3 and Fto Using a Nex-CreERT2 Driver Line Have Impaired Fear Coping, Differential Transcriptional Response to Fear, and Changes in Hippocampus CA1 Electrophysiological Properties](image)

(A) Both Mettl3 cKO and Fto cKO animals display increased conditioned fear memory long-term maintained during fear extinction. The primary fear response was not altered. Fto cKO animals also have increased contextual fear memory. No difference was observed in the Y-maze test or the object recognition test (ORT). CS, conditioned stimulus; lightning bolt, US, unconditioned stimulus; Ext, extinction. n = 11–13, mean ± SEM. Fear expression was binned in 1 min intervals during CS representation. Asterisk (*) depicts a main genotype effect in repeated-measurements ANOVA for CS and Ext bins and a t test $p < 0.05$ for all other data points.

(B) The transcriptomic response 24 hr after fear conditioning (FC) is altered in both animals with Mettl3 or Fto depletion. log2 RNA fold change in WT versus cKO animals of only those genes with a significant genotype × FC effect. Q < 0.1, absolute log2 fold change > 0.5, n = 5.

(C) More genes express a genotype-dependent FC effect in Fto cKOs compared to Mettl3 cKOs with low overlap. Four examples of such genes are shown. Significant genotype × FC in the examples is depicted by blue (Mettl3 cKOs) and pink (Fto cKOs) opposite arrows. Q < 0.1, absolute log2 fold change > 0.5, n = 5.

(D) Long-term potentiation (LTP), but not short-term plasticity, in CA1 was attenuated in Fto cKO mice, but not Mettl3 cKO mice. Short-term synaptic plasticity was measured by paired-pulse facilitation (PPF). n = 10–12 slices from 5–6 animals, mean ± SEM plus representative LTP trace curves; HFS, high-frequency stimulation. *$p < 0.05$, t test, on the average field excitatory postsynaptic potential (fEPSP) slope 50–60 min post-HFS.

See also Figures S6 and S7 and Table S4.
the transcriptome-wide gene expression values as published in Arloth et al. (2015) using CellCODE. For the samples used for the m\(^6\)A/m measurements, cell estimates were not found to be significantly different (Figure S8A; no significant effects for dexamethasone within any of the cell types or significant effect of the cell types on the dexamethasone x diagnosis x sex interaction, dexamethasone x diagnosis interaction, or dexamethasone main effects was observed). Using the cell estimates for the analysis of global m\(^6\)A/m confirms the earlier observed effect of dexamethasone dependent on subject MDD diagnosis (significant interaction effect of treatment and subject status [F1, 96] = 10.251, p = 0.002), but no interaction with sex or any significant covariate effect of cell type estimates.

To control for potential contamination of results by antidepressant treatment present in blood of MDD patients, we performed m\(^6\)A/m-seq of BLCLs treated for 1 hr with 100 nM cortisol or mock treatment (n = 3 per genotype and treatment). BLCL m\(^6\)A/m peaks were again found to be very similar across the different groups (Figures S9A and S9B), with typical m\(^6\)A/m properties regarding distribution and consensus motif (Figures S9B and S9C). m\(^6\)A/m in BLCL are enriched in genes related to stress regulation and metabolic functions (Figure 8A). Analyzing the differential response to cortisol of

![Figure 7. Global m\(^6\)A/m in Blood Is Transiently Decreased after Stress in Mice and after Stimulation with GCs in Healthy Humans, but This Glucocorticoid-Induced m\(^6\)A/m Reduction Is Absent in Blood and BLCLs from MDD Patients](image-url)
an m6A/m consensus peak set (17,665 m6A/m peaks), in line with the results of the global m6A/m measurements, we observed major changes of m6A/m by cortisol in both a donor-dependent fashion (donor × treatment interaction effects) and a donor-independent fashion (main cortisol effects), but almost no significant differences by donor status alone, as well as a higher number of...
cortisol-regulated m^6^A/m peaks in healthy compared to MDD donor cell lines (Figures 8B and 8C; Table S5; example peaks in Figure S3D; top 25 regulated m^6^A/m peaks and RNAs in Figures S3F and S3G; all Q < 0.1, absolute log2 fold change > 0.5). Cortisol main and donor-interaction-regulated m^6^A/m peaks both showed a preference for location in the CDS and 5’ UTR (Figure 8D) with the donor-dependent cortisol-regulated peaks enriched in catabolic genes (Figure S3E), i.e., genes involved in energy-providing metabolic processes. Similar to the regulation of global m^6^A/m being more prominent in healthy donor BLCLs, m^6^A/m peaks regulated by cortisol were most often regulated in cells from healthy rather than MDD donor cells (Figures 8C and 8E).

Finally, to confirm the differential regulation of m^6^A/m levels in BLCLs from healthy and MDD donors, we performed m^6^A/m-RIP-qPCR testing for GC-responsive genes in BLCLs after stimulation with cortisol. We observed specific downregulation of m^6^A/m in FKBP5, IRS2, and TSC22D3 in cells from healthy, but not from MDD, individuals (Figure 8F). In line with the general trends observed before, methylation of tested candidates in cells derived from healthy, but not MDD, donors was significantly decreased (Figure 8G).

**DISCUSSION**

Here, we have identified m^6^A and m^6^Am as epitranscriptomic marks responsive to acute stress. Using m^6^A/m-seq in mouse cortex and m^6^A/m profiling in smaller areas by m^6^A/m-RIP-qPCR, we provide a map of brain m^6^A/m and evidence for regulation of m^6^A/m by acute stress. Consequently, in mice with METTL3 and FTO depleted in adult excitatory neurons and consequently altered m^6^A and m^6^Am profiles, we observed changes in transcriptome regulation, behavior, and electrophysiological properties. Finally, we observed that regulation of m^6^A/m and its cellular machinery in blood may represent a peripheral proxy for part of the brain’s m^6^A/m responses that seems impaired in patients with a stress-related disorder, MDD.

In the m^6^A/m-seq of mouse cortex, we remapped mouse cortical m^6^A/m, describing a higher amount of 5’ UTR peaks than previously reported (Meyer et al., 2012). A part of these 5’ UTR peaks may represent m^6^A/m sites, although we did not observe any different properties of these putative m^6^A/m peaks compared to general m^6^A/m peaks. We further add the observation that m^6^A sites in vivo overlap with the neuronal RNA-binding and cell-transport-regulating protein FMRP/FMR1-binding sites. FMR1 has recently been shown to bind m^6^A/m (Edupuganti et al., 2017), suggesting that it may be an important m^6^A reader in the brain. Future work is needed to investigate the nature of FMR1 binding to m^6^A/m and the effects of this binding in neurons, including potential roles in transcript localization to specialized neuronal compartments as axons and dendrites and potential regulation of local synaptic translation. Investigating a potential general relation of stress-regulated m^6^A/m regulating transcript translation, we could not find evidence for this.

Overall, only a very small number of m^6^A/m peaks in m^6^A/m-seq was found to be stress regulated. This is likely due to the large cellular heterogeneity of the material used; thus, only a small fraction of cells would have been responsive to the treatment and thus there was limited sensitivity of the assay to detect changes. Indeed, we find that m^6^A/m regulation is highly specific to smaller brain areas with even often opposite regulation in different areas as shown in the example of PFC being globally hypomethylated after stress and the AMY globally hypermethylated; this effect was confirmed by specific m^6^A detection being majorly driven by m^6^A. These two areas regulate behavioral and hormonal stress responses, fear, and anxiety (McEwen et al., 2015), with the PFC exhibiting top-down control of the AMY in anxiety and fear in mice (Adhikari et al., 2015). These changes were accompanied by matching regulation in the demethylase Fto and Alkbh5 expression, as well as regulation of the methyltransferase Mettl3. Interestingly, previous reports also showed transcriptional regulation of Fto after acute stress by fear conditioning (Walters et al., 2017; Widagdo et al., 2016).

Although we observed a general negative correlation between absolute m^6^A/m change and RNA abundance in m^6^A/m-RIP-qPCR, most m^6^A/m changes were not accompanied by significant transcript changes in m^6^A/m-RIP-qPCR or m^6^A/m-seq, implying that differential m^6^A/m acts by regulating both RNA decay and location and translation control.

Notably, we observe that corticosterone i.p. injection in mice causes similar effects on m^6^A/m and enzyme expression as acute stress, pointing toward a potential signaling mechanism via centrally acting GCs. Additional work is needed to unravel the pertinent signaling cascades involved. It is currently unclear which of the cell types drive the observed effects on m^6^A/m, with likely all major brain cell types having m^6^A/m and expression of the respective machinery genes (as observed by single-cell RNA-seq; data not shown).

To more specifically investigate the mechanisms of m^6^A/m methylation in adult excitatory neurons only, we employed cKO mice using Camk2α-Cre and Nex-CreERT2 drivers. Interestingly, while METTL3 deletion reduced m^6^A as expected, FTO deletion did not alter m^6^A levels but increased m^6^A/m levels. However, m^6^A/m peaks differentially methylated in Fto cKO mice were not only positioned at the 5’ UTR, but also in CDS and 3’ UTR, pointing at FTO not only affecting m^6^A/m, but a large part (Mauer et al., 2017). In general, epitranscriptomic and transcriptomic signatures of Mettl3 cKO and Fto cKO brain tissue were substantially different, indicating that both enzymes in neurons of the adult brain have different targets and likely very different functions. Interestingly, both Nex-CreERT2 knockout mice had very similar behavioral profiles, including lack of effects on anxiety and general cognition but increased fear memory for cued fear (with Fto cKO mice additionally having increased contextual fear) with stable differences of memory across time and fear extinction training, extending the previously reported fear expression upon knockdown of Fto in the dorsal hippocampus (Walters et al., 2017) and in the PFC (Widagdo et al., 2016). This indicates that fear-memory acquisition as well as its stability to extinction may require fine-tuned regulation of m^6^A/m levels rather than being directly regulated by specific m^6^A/m levels at specific genes. Mechanistically, we found that Mettl3 and Fto depletion alters not only the steady-state transcriptome in adult hippocampal neurons, but also the transcriptomic response to the fear conditioning stress, including regulation of several genes.
involved in neuronal circuit function and pointing out a function of m^6^A/m in regulating neuronal circuits. Consequently, we describe that network plasticity is specifically altered in the CA1, a brain region crucial for contextual fear, in Fto cKO, but not Mettl3 cKO, mice. This may reflect a neuronal correlate of altered m^6^A/m underlying the altered contextual fear memory observed in Fto cKO mice.

Finally, we propose that regulation of m^6^A/m and its cellular machinery in blood may represent a peripheral proxy for part of the brain’s m^6^A/m response, similar to DNA methylation changes (Ewald et al., 2014; Provençal et al., 2012). Both mice and humans showed global blood demethylation after stress or GC intake, respectively. The m^6^A/m response to GCs is impaired in blood cells obtained from MDD patients, which may be a consequence of the altered GC receptor downstream signaling reported in MDD (de Kloet et al., 2005). While limited in sample size, these data represent a first step for future studies aiming to assess m^6^A/m in human samples as potential biomarkers or for mechanistic investigations and show the feasibility of such studies. Interestingly, genetic variants in FTO (Milaneschi et al., 2014; Samaan et al., 2013) and ALKBH5 (Du et al., 2015) have been reported to associate with risk for MDD before but are yet to be replicated in larger cohorts. Growing evidence supports fine-tuning of transcriptional regulation is critical for psychiatric disorders including various epigenetic mechanisms (Klengel and Binder, 2015). Here, we reveal RNA modifications as a novel mechanism relevant for understanding psychiatric disorders.

In summary, m^6^A and m^6^Am methylation constitute a novel layer of complexity in gene expression regulation following stress exposure, which is pivotal for the adaptation of stress-responsive circuits to acute challenges. The exciting finding of m^6^A/m dysregulation in MDD opens the possibility for the development of novel diagnostic biomarkers and eventually to better treatments for anxiety disorders, depression, and other stress-related diseases.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Animals
  - Sample collection
  - Cell culture
  - Human blood
- **METHOD DETAILS**
  - RNA isolation
  - Global m^6^A/m measurements
  - LC-MS/MS
  - m^6^Am-Seq
  - Ribosome profiling
  - mRNA-Seq
  - Gene expression
  - Upstream GRE prediction
  - Spike-in Oligo
  - Candidate m^6^A/m-RIP-qPCR
  - Human microarray data
  - Human blood cell estimates
  - Animal behavior testing
  - Electrophysiology
  - In situ hybridization
  - Western Blot

**QUANTIFICATION AND STATISTICAL ANALYSIS**

- m^6^A/m-Seq analysis
- Putative m^6^Am
- Ribosome profiling analysis
- mRNA-Seq analysis
- Gene expression analysis
- Candidate m^6^A/m-RIP-qPCR analysis
- Statistical analysis

**DATA AND SOFTWARE AVAILABILITY**

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes nine figures and five tables and can be found with this article online at https://doi.org/10.1016/j.neuron.2018.07.009.

**ACKNOWLEDGMENTS**

We thank T. Namendorf, E. Wagner, B. Hauger, C. Dournes, A. Mederer, A. Ressle, A. Par, and D. Harbich for their technical support and A. Varga and the animal care team for their devoted assistance with animal care. We thank S. Karamihaleh, M. Filiou, A. Menke, and A. Genevsky for helpful discussions and J. Keverne for professional English editing. We thank G. Rechavi, S. Mosnitch-Moshkovitz, V. Hershkovitz, E. Feldmesser, and G. Steitzer for guidance with preparing and/or analyzing m^6^A/m-seq libraries and for helpful discussions. A.C. is the head of the Max Planck Society – Weizmann Institute of Science Laboratory for Experimental Neuropsychiatry and Behavioral Neurogenetics. This work was supported by travel grants from the Boehringer Ingelheim Fonds (M. Engell); the European Research Council (FP7 (grant 280463); the Israel Science Foundation (1565/15); the ERANET Program, supported by the Chief Scientist Office of the Israeli Ministry of Health (3-11389); the Federal Ministry of Education and Research (01KU1501A); research support from Roberto and Renata Ruhanan and Bruno and Simone Licht; the I-CORE Program of the Planning and Budgeting Committee and the Israel Science Foundation (1916/12); the Nella and Leon Benzoziyo Center for Neurological Diseases; the Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics; the Perlman Family Foundation; the Adelis Foundation; the Irving I. Moskowitz Foundation (all previous to A.C.); the Israel Science Foundation (355/17 and 107/14, J.H.H.); and FAMRI and NYSCF grants (J.H.H).

**AUTHOR CONTRIBUTIONS**

M. Engell and A.C. conceived and designed the experiments and wrote the manuscript. M. Engell performed and analyzed most experiments including m^6^A/m-seq; bioinformatics; m^6^A-RIP-qPCR; and mouse, behavior, and cell culture experiments. C.E., P.M.K., L.T., and M.R.-H. assisted in experiments. M. Eder performed and analyzed electrophysiology experiments. M. Engel and A.C. conceived and designed the experiments and wrote the manuscript. The study was supervised by A.C.

**DECLARATION OF INTERESTS**

The authors declare no competing interests.
REFERENCES


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>polyclonal rabbit anti-m6A (and m6Am)</td>
<td>Synaptic Systems</td>
<td>202 003; RRID: AB_2279214</td>
</tr>
<tr>
<td>polyclonal rabbit anti-METTL3</td>
<td>Proteintech</td>
<td>15073-1-AP; RRID: AB_2142033</td>
</tr>
<tr>
<td>monoclonal mouse anti-FTO</td>
<td>Merck Millipore</td>
<td>MABE227; RRID: AB_11203491</td>
</tr>
<tr>
<td>polyclonal rabbit anti-ACTB</td>
<td>Cell Signaling Technology</td>
<td>4967; RRID: AB_330288</td>
</tr>
<tr>
<td>monoclonal rabbit anti-GR</td>
<td>Abcam</td>
<td>ab109022; RRID: AB_10863164</td>
</tr>
<tr>
<td>polyclonal rabbit anti-BTUB</td>
<td>Abcam</td>
<td>ab6046; RRID: AB_2210370</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>corticosterone-HBC complex</td>
<td>Sigma</td>
<td>C174</td>
</tr>
<tr>
<td>Dexa-ratiopharm</td>
<td>Ratiopharm</td>
<td>Dexamethasone injection solution 59988.00.00</td>
</tr>
<tr>
<td>cycloheximide</td>
<td>Sigma</td>
<td>C7698</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EpiQuik m6A RNA Methylation Quantification Kit (Colorimetric)</td>
<td>Epigentek</td>
<td>P-9005-96</td>
</tr>
<tr>
<td>TruSeq Stranded mRNA Library Prep Kit</td>
<td>Illumina</td>
<td>RS-122-2103</td>
</tr>
<tr>
<td>TruSeq Ribon profile for Mammalian</td>
<td>Illumina</td>
<td>RPHMR12126</td>
</tr>
<tr>
<td>QuantFast SYBR Green PCR Kit</td>
<td>Qiagen</td>
<td>204057</td>
</tr>
<tr>
<td>Taqman Fast Advanced Master Mix</td>
<td>Applied Biosystem</td>
<td>4444965</td>
</tr>
<tr>
<td><strong>Deposited Data</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>superseries</td>
<td>This paper</td>
<td>GEO: GSE113801</td>
</tr>
<tr>
<td>m6A/m-Seq mouse cortex after acute stress</td>
<td>This paper</td>
<td>GEO: GSE113781</td>
</tr>
<tr>
<td>Ribosome profiling Seq mouse cortex after acute stress</td>
<td>This paper</td>
<td>GEO: GSE113789</td>
</tr>
<tr>
<td>m6A/m-Seq of mouse adult cortex of Mettl3 cKO or Fto cKO mice</td>
<td>This paper</td>
<td>GEO: GSE113793</td>
</tr>
<tr>
<td>mRNA-Seq of mouse Mettl3 cKO or Fto cKO mouse hippocampus after fear conditioning</td>
<td>This paper</td>
<td>GEO: GSE113796</td>
</tr>
<tr>
<td>m6A/m-Seq of human B-lymphocyte cell lines from healthy controls and major depressive disorder patients</td>
<td>This paper</td>
<td>GEO: GSE113798</td>
</tr>
<tr>
<td>FMR1 bound genes</td>
<td>Darnell et al., 2011</td>
<td>Supplemental Data</td>
</tr>
<tr>
<td><strong>Experimental Models: Cell Lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human immortalized BLCLs from patients</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>10-12 w old adult male mice C57BL/6</td>
<td>Charles River</td>
<td>027</td>
</tr>
<tr>
<td>Mettl3 cKO mice</td>
<td>Mettl3&lt;sup&gt;tm1a(KOMP)Wtsi&lt;/sup&gt; v6.5 mouse ESCs targeted as described in mice generated by GeuLa et al., 2015</td>
<td>Mettl3&lt;sup&gt;tm1c(KOMP)Wtsi&lt;/sup&gt;</td>
</tr>
<tr>
<td>Fto cKO mice</td>
<td>Fto&lt;sup&gt;tm1a(EUCOMM)Wtsi&lt;/sup&gt; EMMA EM: 05094</td>
<td>Fto&lt;sup&gt;tm1c(EUCOMM)Wtsi&lt;/sup&gt;</td>
</tr>
<tr>
<td>Camk2a-Cre mice</td>
<td>Minichiello et al., 1999</td>
<td>Tg&lt;sup&gt;Camk2a-cis-cre;IRES2kdn&lt;/sup&gt; MGI:2176754</td>
</tr>
<tr>
<td>Nex-CreERT2 mice</td>
<td>Agarwal et al., 2012</td>
<td>Neurod2&lt;sup&gt;tm2.1(cis;cre)/ERT2Kan&lt;/sup&gt; MGI:5308766</td>
</tr>
<tr>
<td>Human blood</td>
<td>Menke et al., 2012; Arloth et al., 2015</td>
<td>“MPIP” and “MARS” cohorts</td>
</tr>
</tbody>
</table>

(Continued on next page)
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alon Chen (alon_chen@psych.mpg.de).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals

All experiments were approved by and conducted in accordance with the regulations of the local Animal Care and Use Committee (Government of Upper Bavaria, Munich, Germany and Weizmann Institute of Science, Rehovot, Israel).

For all experiments characterizing m6A/m changes after stress, 10-12 w old adult C57 BL/6 male mice were used (Charles River, Sulzfeld, Germany). Mettl3 CKO and Fto ckO mice were generated by breeding Mettl3tm1a(KOMP)Wtsi lox/lox mice (derived from Mettl3tm1a(KOMP)Wtsi V6.5 mouse ESCs targeted as described in mice generated by Geula et al., 2015) or Ftotm1a(EUCOMM)Wtsi obtained from EMMA (EM: 05094) to Camk2a-Cre mice (Minichiello et al., 1999) or Nex-CreERT2 mice (Agarwal et al., 2012), respectively. Camk2a-Cre mice crossed mice were used for LC-MS/MS and m6A/m Seq (Figure 4), Nex-CreERT2 crossed mice were used for mRNA-Seq, behavioral characterization and electrophysiological characterization (Figures 5 and 6). Experimental mice were homozygous floxed Cre-positive (Cre+/+, “cKO”) and Cre-negative (+/+, “WT”) littermates generated by breeding of homozygous floxed mice negative and hemizygous for the CreERT2-allele. All Nex-CreERT2 crossed mice were fed with tamoxifen-containing chow (Genobios LASCR diet Cre Active TAM 400) starting at the age of 4-6 w.
Animals were housed in groups, until being single housed 7 d before the experiments started, in standard plastic cages and maintained in a temperature-controlled environment (21 ± 2°C) on a 12 hr light/dark cycle with food and water available ad libitum. Restraint stress was performed for 15 min in ventilated 50 mL falcon tubes, starting at 2 hr post lights on. For pharmacological studies, mice were injected with vehicle solution (saline), 250 μg/kg corticosterone (corticosterone-HBC complex, Sigma) or 10 mg/kg dexamethasone (Ratiopharm Dexa-ratiopharm) i.p. 2 hr post switching the lights on.

Sample collection
Whole mouse cortex for m6A/m-Seq was collected at designated time points by manual dissection of fresh brains on ice. For each sample, 3 animals randomly selected from the same group were pooled. For investigation of regions-specific effects in PFC and AMY, brains were immediately flash-frozen after dissection and defined tissue punches of medial prefrontal cortex (PFC; consisting of infralimbic and prelimbic cortex) and amygdala (AMY; consisting of central and basolateral amygdala) were collected using a 1 mm round tissue punch while sectioning brains on a cryostat. Mouse whole blood was collected in EDTA tubes, aliquoted and flash-frozen.

Cell culture
Human immortalized BLCLs derived from age-matched (33-53 y) male subjects either healthy or diagnosed with MDD were cultured in RPMI-1640 medium (Merck KGaA, Darmstadt, Germany) supplemented with 10 % fetal calf serum at 37°C with 5% CO2. The cells were tested to be free of mycoplasma. Cells were treated with cortisol (Sigma-Aldrich, St. Louis, MO, in ethanol, final concentration 0.1% v/v) or dexamethasone (Ratiopharm, in saline), or ethanol or saline mock control, respectively.

Human blood
Human whole blood was collected using PAXgene Blood RNA Tubes (PreAnalytiX, Hombrechtikon, Switzerland) either unstimulated or after oral administration of 1.5 mg dexamethasone and processed as described previously (Menke et al., 2012). Age-matched healthy Caucasian male and females subjects were selected from the “MPIP” and “MARS” cohorts described previously (Arloth et al., 2015; Menke et al., 2012).

METHOD DETAILS

RNA isolation
Total RNA from tissue, mouse blood and BLCL cells was purified using Trizol (Invitrogen, Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions followed by isopropanol precipitation. For mouse whole blood, RNA was isolated using a 1:10 ratio of blood to Trizol.

Global m6A/m measurements
Global m6A/m in total RNA was quantified by the EpiQuik m6A/m RNA Methylation Quantification Kit (Epigentek Group, Farmingdale, NY) following manufacturers’ specifications and using 100-300 ng input (in duplicates or triplicates). Comparing total RNA global m6A/m measurements with LC-MS/MS data from the same conditions, we observed high correlation of stress-changes, suggesting that the total RNA colorimetric assay represents an appropriate tool to detect global m6A/m regulation patterns. Brain global methylation in PFC and AMY is not regulated by circadian rhythm (data not shown).

LC-MS/MS
For profiling of m6A after acute stress, samples were pooled from 4 mice randomly selected from the same group and RNA isolated as stated above. For profiling of m6A and m6Am in cKO mice, RNA from the samples processed for m6A/m-Seq (pooled from 3 mouse cortex each) were used. For profiling of m6A from BLCLs, RNA from cells of each of the BLCL lines was isolated as stated above. Residual genomic DNA was removed using the TurboDNA-free kit (Ambion, Life Technologies, Carlsbad, CA). RNA integrity and absence of DNA was confirmed by Bioanalyzer RNA Nano chips (Agilent Technologies, Santa Clara, CA, mRNA mode; less than 4% rRNA content). For cKO mice m6A and m6Am profiling, PolyA+ RNA was prepared using 2 rounds of the Genelute mRNA Prep Kit (Sigma-Aldrich, St. Louis, MO) with rRNA depletion confirmed by Bioanalyzer RNA Nano chips (Agilent Technologies, Santa Clara, CA, mRNA mode; less than 4% rRNA content). For cKO mice m6A and m6Am profiling, PolyA+ RNA was prepared using 1 round of the Genelute mRNA Prep Kit (Sigma-Aldrich, St. Louis, MO) and one round of RiboZeroGold rRNA depletion (Illumina, San Diego, CA) with RNA removal confirmed by Bioanalyzer RNA Nano chips (Agilent Technologies, Santa Clara, CA, mRNA mode; no rRNA detected). 250 ng PolyA-RNA (acute stress, BLCLs) or 500 ng PolyA-RNA (cKO mice) per sample and a standard curve (acute stress, BLCLs: N6-methyladenosine/adenosine, cKO mice: all standards see Figure S4B) were mixed with deuterated N6-(methyl-d3)-adenosine as an internal spike-in calibrator. The RNA-spike-in-mix from cKO mice was first decapped with 25 U RppH (NEB, Ipswich, MA) in the supplied buffer with 1 μlRNasin and 0.1% TritonX buffer added for 2 hr at 37°C and purified with 4x RNAClean XP (Agencourt Beckman Coulter, Brea, CA). Mouse acute stress and BLCL PolyA mixed with the spike-in calibrator as well as the decapped cKO mouse RNA mix was processed to nucleosides as reported before (Jia et al., 2011): Samples were treated with 2 U P1 nuclease at 37°C for 1 hr, followed by addition of Na2HCO3 and treatment.
with 0.5 U alkaline phosphatase (all Sigma-Aldrich, St. Louis, MO), at 37 °C for 2 hr. Samples at a final concentration of 250 ng in 25 μl were filtered through a Corning Spin-X 0.2 um sterile cellulose acetate filter (Corning, Corning, NY) and diluted 1:10 with 20% methanol. HPLC/MS-MS analysis was performed using a Shimadzu Nexera X2 (Shimadzu, Duisburg, Germany) liquid chromatograph interfaced to the ESI source of a Sciex QTrap 5500 (Sciex, Darmstadt, Germany) triple quadrupole mass spectrometer. Chromatography was accomplished using a gradient elution in a Accucore RP-MS column (100 x 2.1 mm, 2.6 μm Thermo Scientific, Dreieich, Germany) at a flow rate of 0.3 ml/min, 5 μl injection volume, at 30 °C for 10 min with the following gradient profile: Eluent A (10 mM NH₄HCO₃, 0.1% CH₃O₂ in CH₃OH) for 3 min with 10% eluent B (10 mM NH₄HCO₃, 0.1% CH₂O₂ in CH₂OH), 4 min 10–95% B, 1 min hold at 95% B, 0.2 min 95%–10% B and 1.8 min 10% B. The ion source was operated in positive mode at 400 °C, and multiple reaction monitoring (MRM) collision-induced dissociation (CID) were performed using nitrogen as the collision gas. Retention times and transitions monitored during analysis for the analytes are shown in Figure S4B. Quantification was performed by comparison with the standard curve obtained from pure nucleoside standards normalized by the deuterated spike-in calibrator run within the same experiment.

m⁶Am₅-m-Seq
For mouse m⁶Am₅-m-Seq, whole mouse cortex samples were used pooling 3 individuals each, since m⁶Am₅-m-Seq on PolyA-RNA of smaller regions did not result in sufficient enrichment quality. For m⁶Am₅-m-Seq of human BLCLs, RNA from each 3 randomly chosen cell lines from healthy and MDD donors each 1 hr after treatment with 100 nM cortisol or mock treatment was used. Each m⁶Am₅-m-Seq experiment had an IgG control using RNA mixed equimolar from all samples of that experiment. m⁶Am₅-m-Seq was performed using a modified version of previously published protocols (Dominissini et al., 2013; Meyer et al., 2012). RNA was isolated using Trizol (Invitrogen, Life Technologies, Carlsbad, CA) and residual genomic DNA was removed using the TurboDNA-free kit (Ambion, Life Technologies, Carlsbad, CA). RNA integrity and absence of DNA was confirmed by Bioanalyzer RNA Nano chips (Agilent Technologies, St. Louis, MO, RIN > 9.5) and Qubit DNA High sensitivity kit, respectively. PolyA+ RNA was prepared using 1 round of the Gentle mRNA Prep Kit (Sigma-Aldrich, St. Louis, MO) with less than 5% residual RNA as confirmed by Bioanalyzer RNA Nano chips (Agilent Technologies, St. Louis, MO, mRNA mode). RNA was fragmented using fragmentation reagent (Life Technologies, Carlsbad, CA), mRNA fragments were precipitated with ethanol and used for m⁶Am₅-m-immunoprecipitation, IgG control and input samples. m⁶Am₅-m-immunoprecipitation (10 μg mRNA fragments mouse acute stress and BLCLs or 7.5 μg mouse cKO and 10 μg rabbit polyclonal anti-m⁶Am₅-m 202 003, lots: /56 for mouse acute stress and BLCLs, /66 for cKO mice, Synaptic Systems, Göttingen, Germany) or IgG control (10 μg mRNA fragments mixed from all samples and 10 μg IgG 2729, Cell Signaling Technology, Beverly, MA) was performed in precipitation buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 0.05 % NP-40, 1 mL total volume) with 1 μL RNasin Plus (Promega, Madison, WI) rotating head over tail at 4 °C for 2 hr, followed by incubation with washed 30 μl Protein A/G beads (Thermo Fisher Scientific, Waltham, MA) rotating at 4 °C for 2 hr. Bead-bound antibody–RNA complexes were recovered on a magnetic stand and washed twice with immunoprecipitation buffer, twice with high-salt buffer (50 mM Tris, pH 7.4, 1 M NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS), and twice with immunoprecipitation buffer. Fragments were eluted by Proteinase K treatment (300 μl elution buffer: 5 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 0.05% SDS, 4.2 μl 20 mg/ml proteinase K). RNA was recovered from the eluate using Trizol LS (Invitrogen Life Technologies, Carlsbad, CA) following manufacturers’ recommendations. Sequencing libraries were prepared using the Illumina TruSeq non-stranded (mouse cortex acute stress and BLCLs) or stranded (cKO mouse cortex) mRNA protocol following the standard protocol starting from mRNA fragments recovered from m⁶Am₅-m-IP, IgG-IP, or 100 ng of original PolyA-RNA input fragments. Libraries were quality-checked using Bioanalyzer DNA High Sensitivity chips (Agilent Technologies, St. Louis, MO) and quantified using the KAPA Library Quantification Kit (KAPA Biosystems, Boston, MA). Sequencing was performed on 2–4 lanes of an Illumina HiSeq4000 PE 2x100 (Illumina, San Diego, CA) multiplexing all m⁶Am₅-m, IgG- and input samples per experimental run.

Ribosome profiling
Ribosome profiling libraries were prepared from mouse cortex of 6 mice 4 hr after acute stress and 6 matching control mice using the TruSeq Ribo Profile (Mammalian) Kit (Illumina, San Diego, CA; based on Ingolia et al., 2014) with the following adjustments: Flash-frozen cortex samples were homogenized in 750 μl lysis buffer including cycloheximide using a dounce homogenizer and 10 passes through a 25 G needle and incubated rotating for 20 min at 4 °C. After centrifugation for 20 min at 20000 * g at 4 °C 100 μl supernatant was used as input for small samples and 400 μl supernatant were processed for ribosome profiling with 45 min incubation at RT with 60 U/OD₂₆₀ Nuclease. After adding 15 μl of RNase inhibitor, monosomes were purified on a sucrose gradient. Ribosome protected fragments as well as input RNA was purified using Trizol LS (Invitrogen, Life Technologies, Carlsbad, CA) and the miRNeasy micro kit (QIAGEN, Hilden, Germany). rRNA was depleted using the RiboZero mammalian Gold Kit (Illumina, San Diego, CA) and fragments size-selected, purified and processed as described. cDNA was purified using a 2.5 x AMPure clean-up (Agencourt Beckman Coulter, Brea, CA). PCR was performed on undiluted circularized cDNA with 12 PCR cycles. PCR products were size-selected on a 5% DNA-TBE PAGE. Sequencing was performed on each one lane for ribosome bound fractions and input fractions (indexed each 1-12 of an Illumina HiSeq4000 PE 2x100 (Illumina, San Diego, CA) using only the reverse read.

mRNA-Seq
Brains were collected from 5 of each of the following: Mettl3 cKO and WT as well as Fto cKO and WT mice 24 hr after fear conditioning (“FC,” details in “Animal behavior testing”) or comparable handling without fear induction (“Box”: handling and exposure to context...
as in “FC” in “Animal behavior testing” but without foot shock and tone/CS and US). The entire CA1 and CA3 was cryo-punched using 0.7 and 1 mm punching tools from snap-frozen brains sliced at 250 μm using a cryostat and RNA isolated. Residual genomic DNA was removed using the TurboDNA-free kit (Ambion, Life Technologies, Carlsbad, CA). RNA integrity and absence of DNA was confirmed by Bioanalyzer RNA Nano chips (Agilent Technologies, St. Louis, MO, RIN > 8.5) and Qubit DNA High sensitivity kit, respectively. mRNA-Seq libraries were prepared from 4 μg total RNA using the Illumina TruSeq stranded mRNA protocol HT (Illumina, San Diego, CA) following the standard protocol starting with Supernscript III and 11 cycles of PCR. Libraries were quality-checked using Bioanalyzer DNA High Sensitivity chips (Agilent Technologies, St. Louis, MO) and quantified using the KAPA Library Quantification Kit (KAPA Biosystems, Boston, MA). Sequencing was performed on 4 lanes of an Illumina HiSeq4000 PE 2x100 (Illumina, San Diego, CA) multiplexing all samples.

**Gene expression**

Gene expression of m^6^A/m-related enzymes was done by SYBR-green-based qPCR. RNA was reverse-transcribed using the SuperScript III VILO cDNA Synthesis Kit (Invitrogen Life Technologies, Carlsbad, CA) and Quantifast SYBR Green PCR Kit (QIAGEN, Hilden, Germany) on a QuantStudio 7 (Applied Biosystems, Waltham, MA) with the following primers: Mettl3 NM_019721 (ATTAGAGA GACTGCCCTCCCTGG, AGCTTTGTAAAGGAATGCGT), Mettl4 NM_201638 (AGACGCCTTCTCTCTTTGG, AGCCCTCGATT TCTCCTG), Wtap_consensus (GTATG GCCAGGGATGTT, ATCTCCTGCTTTGTTG), Wtap_short NM_00113532 (CTAG CAACCAAAAGAAGGAGAAGA, AGCTTGTACGTTTCAGATA), Wtap_long NM_00113532 (GGGAAAAGCTAAAGGCCAA, GCTGTCGTGCTCTCCTCA), Tnf NM_015736 (CATTATGGAGGGCCAGGA, AGATGCAACAATACCGCC), Yhfd1 NM_145393 (ACCAACTCTAGGAGACCTCA, GATAAAAGAAGATGACAAGG), Yhfd2 NM_172677 (TGCACATTATTAAAAGGCGTA, Yhfd3 NM_172677 (TGCACATTATTAAAAGGCGTA, Yhfd4 NM_016884 (TGCACATTATTAAAAGGCGTA, Yhfd5 NM_016884 (TGCACATTATTAAAAGGCGTA, Yhfd6 NM_016884 (TGCACATTATTAAAAGGCGTA). Each qPCR assay was performed in duplicates or triplicates with a standard dilution curve of a calibrator and using assay efficiency for calculations. Expression levels were quantified by the ddCT method normalizing to an average of 4-5 housekeeping genes based on maximum stability between the following: Hprt NM_013556 (ACCTCTCAAGGGATGGTACAGG, CTTGCGCTACATCTCTTTG), Rpl13A NM_012423 (GCGTCTGAAGCCTACAAGAA, CCTGTTTCCGTAGCCTCATG), SDHA NM_004168 (CAACAG, TTCAACAGGGTGTTCTCACG) with housekeeping genes TBP NM_003194 (GGGAGCTGTGATGTGAAGTT, GAGCCAT CACGGAAAGAGAAGGC). For human samples, the following primers were used: NR3C1 NM_000176 (CAGCAGTGAAATGGG CAGCAGTGAAATGGG, CAGTCAGCCTCGTTCAAAGT). All assays were designed as intron-spanning if possible with product sizes confirmed by melting curves and band detection on gel showing the absence of genomic DNA products.

**Upstream GRE prediction**

10 kb upstream sequences of m^6^A/m-related genes were done by Biomart (Smedley et al., 2015). GC response elements were predicted by the JASPAR vertebrate core transcription factor binding site prediction (Mathelier et al., 2016) querying NR3C1 motifs predicted by the JASPAR vertebrate core transcription factor binding site prediction (Mathelier et al., 2016) querying NR3C1 motifs.

For human samples, the following upstream sequences were retrieved using Biomart (Smedley et al., 2015). GC response elements were predicted by the JASPAR vertebrate core transcription factor binding site prediction (Mathelier et al., 2016) querying NR3C1 motifs predicted by the JASPAR vertebrate core transcription factor binding site prediction (Mathelier et al., 2016) querying NR3C1 motifs.

**Spike-in Oligo**

The spike-in RNA oligo was designed with the following specifications: 100 bp length, 3 internal m^6^A/m sites within GGAC motif flanked by the most frequent nucleotides 5’ U/A, 3’ A/U, not complementary to hsa or mmu RefSeq mRNA or genome, secondary structure exposing m^6^A/m sites, mean % GC = 51. The sequence is GCAGGACAGAGGAGGAAAGGA, GGAGCATGAGGAAAGGAGG. For human samples, the following upstream sequences were retrieved using Biomart (Smedley et al., 2015). GC response elements were predicted by the JASPAR vertebrate core transcription factor binding site prediction (Mathelier et al., 2016) querying NR3C1 motifs predicted by the JASPAR vertebrate core transcription factor binding site prediction (Mathelier et al., 2016) querying NR3C1 motifs.

**Candidate m^6^A/m-RIP-qPCR**

To validate m^6^A/m-Seq experiments, candidates were chosen from the list of differentially methylated transcripts selecting for transcripts. For investigation of candidate transcript methylation in small brain areas, candidate lists were constructed by intersecting microarray results of mouse brain PFC, AMY and hippocampus after acute stress and GC stimulation (Arloth et al., 2015) with genes
known to be methylated in mouse brain (Hess et al., 2013; Meyer et al., 2012) and functional annotation GO-terms. For investigation of candidate transcript methylation in BLCL cell lines, dexamethasone-responsive genes from human blood microarray data (Arloth et al., 2015) were intersected with BLCL m6A/m-Seq data (unpublished data).

15 μg PolyA-RNA (m6A/m-Seq validation) or 3 μg total RNA (candidate m6A/m-RIP-qPCR validation) or 1.5 μg total RNA (brain area/cell line candidate m6A/m-RIP-qPCR) was mixed well with 30 fmol or indicated amount of spike-in or 3 fmol spike-in, respectively, and equally split into 3 conditions: m6A/m-RIP, IgG control and input. For m6A/m-Seq validation and brain are candidate transcript methylation in BLCL cell lines, dexamethasone-responsive genes from human blood microarray data (Arloth et al., 2015) were intersected with BLCL m6A/m-Seq data (unpublished data). m6A/m-RIP and IgG control samples were incubated in parallel to m6A/m-Seq with 1 ml total volume) with 1 L RNasin Plus (Promega, Madison, WI) rotating head over tail at 4 °C for 2 hr, followed by incubation with washed 25 μL Dynabeads M-280 (Sheep anti-Rabbit IgG Thermo Fisher Scientific, Waltham, MA, Cat11203 D) rotating head over tail at 4 °C for 2 hr. Bead-bound antibody-RNA complexes were recovered on a magnetic stand and washed twice with immunoprecipitation buffer, twice with high-salt buffer, and twice with immunoprecipitation buffer. RNA was eluted directly into Trizol and input RNA was also taken up in Trizol. RNA from all conditions was purified in parallel using the miRNeasy micro RNA isolation kit (QIAGEN, Hilden, Germany) including a 3-time repeated elution 15 mL H2O to ensure the complete elution of all RNA. The entire eluate was transcribed to cDNA using the SuperScript III VLO cDNA Synthesis Kit (Invitrogen, Life Technologies, Carlsbad, CA). Gene expression was quantified using TaqMan Fast Advanced Master Mix (Applied Biosystems, Waltham, MA) on a Quantstudio 7 (Applied Biosystems, Waltham, MA) by the following Taqman gene expression assays: Actb NM_007393 (Mm01205647_g1), Akt1 NM_009652 (Mm01313626_m1), Arc NM_018790 (Mm01204954_g1), Atp1b1 NM_009721 (Mm00437612_m1), Bsn NM_007567 (Mm00464452_m1), Camk2a NM_009792 (Mm00437967_g1), Camk2n1 NM_025451 (Mm01718423_s1), Cited1 NM_007709 (Mm01235642_g1), Cnr1 NM_007726 (Mm01212171_s1), Cnr2 NM_205679 (Mm04206019_m1), Cribp1 NM_199840 (Mm01283832_m1), Crhr1 NM_007762 (Mm00432670_m1), Ctsb NM_007798 (Mm01310508_g1), Cyp2f2 NM_133769 (Mm00460148_m1), Dlg4 NM_007764 (Mm00492193_m1), Dmnt1 NM_001199433 (Mm01151063_m1), Dusp1 NM_013642 (Mm00457274_g1), Egr3 NM_018781 (Mm00516979_m1), Fkbp5 NM_010220 (Mm00487406_m1), Fscn1 NM_007984 (Mm00456064_m1), Fth1 NM_073181 (Mm00436020_g1), Gabbr1 NM_019439 (Mm00444578_m1), Gabbr2 NM_001081141 (Mm01352561_m1), Gadd45g NM_011817 (Mm01352550_g1), Gm1 NM_001114333 (Mm00810219_m1), Grm3 NM_181850 (Mm01316764_m1), Homer1 NM_011982 (Mm00516275_m1), Htra1 NM_019564 (Mm00479887_m1), Htt NM_019914 (Mm00480176_m1), Igf2r NM_198862 (Mm01245481_m1), Nodal NM_013611 (Mm00443040_m1), Notumos NM_022781 (Mm00845023_s1), Nrc3 NM_008173 (Mm00438332_m1), Nr4a1 NM_010444 (Mm01300401_m1), Nrcam NM_176930 (Mm00663607_m1), Nrxn1 NM_020252 (Mm03808856_m1), Nrxn2 NM_020253 (Mm01236844_g1), Oneuc1t NM_008629 (Mm00839394_m1), P2ry13g NM_028808 (Mm00546978_m1), Plekhg3 NM_153804 (Mm00770086_m1), Plin4 NM_020568 (Mm00491061_m1), Pomc NM_008895 (Mm00435874_m1), Prkcb NM_008855 (Mm00435749_m1), Prkcg NM_011102 (Mm00440861_m1), Prf3 NM_021495 (Mm01342993_m1), Rgs4 NM_009062 (Mm00501392_g1), Rhou NM_133955 (Mm00505976_m1), Sgk1 NM_001161850 (Mm00441387_g1), Sgk2 NM_013731 (Mm00449845_m1), Sirt2 NM_022432 (Mm01149204_m1), Spats1 NM_027649 (Mm01270591_g1), Sumo1 NM_009460 (Mm01609844_g1), Syn1 NM_013680 (Mm00449772_m1), Synap1 NM_001281491 (Mm01306145_m1), Tec NM_013689 (Mm00443230_m1), Tsc22d3 NM_0077364 (Mm00726417_s1). Mouse housekeeping genes: Hprt1 NM_00119556 (Mm03024075_m1), Rpl13a NM_009438 (Mm01612987_g1), Tbp NM_013684 (Mm01277045_m1), Ubc NM_011664 (Mm02525934_g1), Uchl1 NM_011670 (Mm00495900_m1). Human gene expression assays: ID3 NM_002167 (Hs00717409_m1), Dusp1 NM_004417 (Hs00610256_g1), Ddit4 NM_019058 (Hs01111686_g1), Gper NM_001505 (Hs01922715_s1), Ir2s NM_003749 (Hs00275843_s1), Kfbps5 NM_004117 (Hs01561066_m1), Nt3c1 NM_000176 (Hs00353740_m1), Tsc22d3 NM_004089 (Hs00608272_m1), Human housekeeping genes: Rpl13a NM_012423 (Hs00149366_g1), Tbp NM_003194 (Hs00427620_m1). The spike-in was quantified using a custom Taqman expression assay (primers TCAATATGGGTTATGGGAC TAAAGC, TGAGGACTACAATCTCAGTTACCA and probe AAGCTGCGAGATTACG). All assays were chosen as intron-spanning if available.

**Human microarray data**

Gene expression of m6A/m-related genes was extracted from microarray expression data of human whole blood published previously (Arloth et al., 2015).

**Human blood cell estimates**

Cell count estimate predictions were done on the gene expression data of the same samples used for m6A/m measurement published previously (Arloth et al., 2015) using CellCode (Chikina et al., 2015) and blood cell transcriptomic reference data (Abbas et al., 2009). The prediction was based on the residuals of the gene expression values (including Dexamethasone as covariant).

**Animal behavior testing**

All behavioral assessments were performed during the light phase. The experimenter was blinded to the genotype of the animals. Retesting followed the order of least-to-most stressful with 2-3 days rest in between tests.
Anxiety-like behavior was assessed using the Open Field Test (OF, 10 min, 10 lux, gray plastic box 50 × 50 × 50 cm, center defined as the inner 25 × 25 cm area), Elevated Plus Maze (EPM 5 min, 10 lux on closed arms, 100 lux on open arms, gray plastic maze 50 × 50 cm elevated 25 cm above the floor), Dark Light Box-Test at baseline (DLB basal) and 4 hr post 15 min restraint stress (DLB 4 hr post stress) (5 min, 100 lux in lit compartment), each with automated tracking (ANY-maze, Stoelting, Wood Dale, IL). The Marble Burying Test was performed by placing the mice in a fresh cage with 5 cm flattened fresh bedding with 15 black, clean marbles spaced evenly across (20 min, 10 lux, counting the number of buried marbles every 5 min). Cognitive function was assessed using the Y maze alternation task for working memory (5 min, 10 lux, Y-shaped 3-arm apparatus with 25 cm arm length and distinguishing visual cues on the walls and at the end of each arm, with automated tracking). The proportion of spontaneous non-repeated subsequent entries into each of the 3 arms (alternations) from the total number of 3-arm entries (including repeat entries) was used as the readout. Non-fear-related memory was assessed using the Object-Recognition-Task (ORT, 2 × 5 min with 1 hr intertrial interval, 10 lux, gray plastic box 50 × 50 × 50 cm, training trial: 2 identical objects with 1 out of 2 objects without object preference randomly assigned to all mice, test trial: 1 known, 1 novel object). The object discrimination ratio DI was determined by DI = (Time with novel object – Time with familiar object) / (Time with novel object + Time with familiar object) within the test trial.

Fear-related memory was assessed by conditional fear learning. Mice were fear conditioned (FC) within the same session for both contextual and cued fear by 180 s of baseline exposure to context A (a metallic/plastic cubic chamber with metal grid conditioned with 70% ethanol smell), followed by a 20 s 80 dB tone (9 kHz sine-wave, conditioned stimulus, CS), which co-terminated with an electric foot shock (unconditioned stimulus, US, 0.7 mA, 2 s, constant current delivered through the metal grid) and a 60 s after-shock interval. Memory was assessed by measuring freezing in response to the different cues by a highly experienced observer blind to the genotype. Auditory cued fear memory was tested 1 day after FC in context B (cylindrical plastic chamber with bedding conditioned with 1% acetic acid) by presenting a 3 min CS after 180 s baseline recording and followed by a 60 s post-tone recording. Freezing across the 180 s tone exposure was binned in 60 s intervals to assess short-term stimulus-habituation. Context memory was tested 2 days after FC in context A without presenting US or CS. Fear extinction was achieved by 10 × 20 s CS presentations (variable intertrial-interval of 20-60 s) in context B on 3 consecutive days 2 w after FC with freezing assessed across the first 3 tone presentations. Fear extinction memory retention was measured 1 w after the extinction by presenting 3 × 20 s CS and measuring the freezing across those 3 presentations. Animals with generalized fear response (over 50% freezing in any of the baseline recordings of the extinctions trials) were excluded from the analysis for extinction memory.

**Electrophysiology**

Recordings were conducted blind to the animal genotype. Preparation of dorsal hippocampal slices and electrophysiological measurements were performed according to standard procedures as described previously (Schmidt et al., 2011). From every animal, 2 slices were used for the experiments.

**In situ hybridization**

Expression quantification of Mettl3 mRNA and Fto mRNA in Mettl3 cKO and Fto cKO animals was performed by in situ hybridization using S-35 labeled antisense probes targeting the fixed exon as described previously (Refojo et al., 2011). Probes were designed for Mettl3 NM_019721 exon 4 (probe cloned using TCAGTCAGGAGATCTAGAGCTATT and CTGAAGTGCAGCTTGCGACA) and Fto NM_019721 exon 4 (probe cloned using TGGCACTGAAATACCTAACACT and ATAGCTGTACACTGCCAGG). Slides were exposed to Kodak Biomax MR films (Eastman Kodak, Rochester, NY), developed, and autoradiographs digitized and quantified by optical densitometry of 2 slides each averaging the signal across both hemispheres and slides utilizing ImageJ (dorsal: Bregma – 1.82, –1.94; ventral Bregma – 3.16, –3.28).

**Western Blot**

Cells or tissue punches were lysed on ice in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8 with Complete, EDTA-free Protease Inhibitor Cocktail Mini, Roche Applied Science, Roche Diagnostics, Indianapolis, IN) for 30 min. 25 μg total protein as determined by the Pierce BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA) (mouse tissue) or Bio-Rad Quick Start Bradford Kit (Bio-Rad Laboratories, Hercules CA) (cells) was heatden for 10 min in SDS/PAGE sample buffer (final concentration 62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercapto-ethanol), separated on a Tris-Glycine SDS–PAGE (Bio-Rad Laboratories, Hercules, CA) and transferred to a nitrocellulose membrane (Amersham Protran, Millipore, Billerica, MA). Membranes were blocked for 1 hr in TBST containing 5% non-fat milk, followed by incubation with primary antibodies overnight at 4°C (anti-METTL3 polyclonal rabbit, 15073-1-AP, 1:200, Proteintech, Rosemont, IL; anti-FTO monoclonal mouse, MABE227 clone 5-2H10, 1:1000, Merck Millipore, Merck KGaA, Darmstadt, Germany; anti-GR polyclonal rabbit, 4967, 1:5000, Cell Signaling Technology, Boston, MA; anti-ACTB polyclonal rabbit, ab109022, 1:50000 Abcam, Cambridge, UK; anti-BTB polyclonal rabbit, ab60646, 1:10000; Abcam, Cambridge, UK) in TBST with 3% non-fat milk. After incubation with horseradish-peroxidase-coupled secondary antibody (anti-mouse or anti-rabbit Cell Signaling Technology, Beverly, MA; 7074) at room temperature for 2 hr, immunoblots were visualized using enhanced chemiluminescence (ECL Plus, GE Healthcare Life Sciences, Freiburg, Germany) detected by the ChemiDoc Imaging System XRS+ (Bio-Rad, Hercules, CA). Detection of BLCL GR and BTUB was done in parallel on horizontally cut blot pieces. For METTL3 and FTO detection in mouse tissue, membranes were first probed with
anti-METTL3 or anti-FTO, stripped after signal detection (0.2 M glycine, 3.5 mM SDS, 1% Tween in H2O 20 min at RT), blocked again and probed with anti-ACTB. Band intensity was quantified using ImageJ.

### QUANTIFICATION AND STATISTICAL ANALYSIS

#### m^6^A/m-Seq analysis

Sequencing data quality control was performed by FASTQC (Andrews, 2010). Genomic alignment was performed using the STAR aligner (Dobin et al., 2013) (to RefSeq mm10 or RefSeq hg38, at default settings) after trimming with cutadapt (Martin, 2011, trimming Illumina adaptors, -q 20, -m 25; employing the “UTAP – User-friendly Transcriptome Analysis Pipeline,” unpublished data). We used exomePeak (Meng et al., 2014) for peak calling each separate m^6^A-RIp/input sample pair (with window_width = 100, sliding_step = 10, minimal_peak_length = 50). Peaks from biological replicates were merged keeping only those ranges supported by a minimum of 2/3 of samples per group (using BEDTools with minimum length 50 nt and merging ranges with less than 50 nt distance, Quinlan and Hall, 2010). Those were the group peaks shown in the supplemental figures. Further analysis of the peaks reveals that the differences in stress and basal are caused by peak-detection thresholds than being true present/absent peaks. For quantification with DiffBind (Ross-Innes et al., 2012) a consensus peak set was built with BEDTools including those ranged supported by either 2/3 of samples per group or 1/2 of samples of the entire experiment, furthermore filtered for minimum abundancy (dba_score_rpkfold = 2, dba_score_reads = 25 for mouse acute stress and BLCLs, = 15 for cKO mice). For differential peak analysis m^6^A/m-RIP counts extracted from DiffBind were compared with DESeq2 (Love et al., 2014; as peak counts in the input samples were not found majorly different we directly compared m^6^A/m counts without subtracting/dividing by counts of input samples thereby keeping the underlying negative binomial distribution). RNA expression was analyzed using the counts from RNA input samples only employing DESeq2 and conducted on gene-level. For acute stress cortex and BLCLs p values were corrected by fdrtool (Strimmer, 2008) based on parameters of the null distribution estimated adaptively from the data (as more than 10% of the original p values were above 0.9). m^6^A/m peaks were considered to be significantly different with an absolute fold change > 0.2 (mouse acute stress) or > 0.5 (mouse cKO and BLCLs) and a Benjamini-Hochberg corrected P value = Q < 0.1. Genes were considered to be significantly different with an absolute fold change > 0.1 (mouse acute stress) or > 0.5 (mouse cKO and BLCLs) and a Benjamini-Hochberg corrected P value = Q < 0.1. Peaks were annotated using ChiPseeker (Yu et al., 2015) and Biomart (Smedley et al., 2015). Distribution-plots of m^6^A/m across the transcript length were evaluated using the Guitar plots (Cui et al., 2016) package. GO-term overrepresentation was calculated using the PANTHER Overrepresentation Test (Mi et al., 2013) for “GO biological process complete” with the list of all detected genes (> 5 rawcounts in all samples) as background. Motif search was performed by DREME (Bailey, 2011) and CentriMo (Bailey and Machanick, 2012) using all detected m^6^A/m-peaks as input (100nt sequences centered on peak). Motifs are presented with B = G/C/T, N = A/C/G/T, W = A/T, Y = C/T. For comparison of the detected mouse m^6^A/m-Seq GGACWB motif with known motifs, we employed Tomtom (Gupta et al., 2007; Ray et al., 2013) and CentriMo (Bailey and Machanick, 2012). Comparison of peaks to known m^6^A/m was done using m^6^A/m data from RMBase v2.0 (Xuan et al., 2018; data as of 2017-06-01). Overlap with FMR1 target genes FMR1 was computed using data from (Darnell et al., 2011) considering only genes expressed in both datasets.

#### Putative m^6^Am

m^6^Am was previously described to be localized to the first nucleotide after the TSS (Schibler and Perry, 1977; Linder et al., 2015; Mauer et al., 2017). Peaks were called putative m^6^Am peaks building up on earlier methods (Linder et al., 2015; Mauer et al., 2017; Schwartz et al., 2014) if the peak start was within a 100 bp window (50 up, 50 down) of an annotated TSS and if there was an INR (YNYWYYY) or TATA box (TATAWAW) motif found in a 75 bp window (50 up, 25 down) around the TSS. These parameters were used to limit false-positive assignment and may underestimate the true extend of m^6^Am peaks.

#### Ribosome profiling analysis

Sequencing data quality control was performed by FASTQC (Andrews, 2010). Genomic alignment was performed on the reverse read only after adaptor- and quality-trimming with cutadapt keeping only those reads with RA5 adaptor present, insert length between 15 and 50 nt and a minimum Phred quality score of 15. The trimmed RPF-sequences were highly enriched for 30-34 nt length. After removing rRNA and tRNA using alignment with Tophat/Bowtie1 to mmu rRNA and tRNA sequences, remaining sequences were aligned using the mouse transcriptome using Tophat/Bowtie1 (Langmead et al., 2009; Trapnell et al., 2009; at default settings to Gencode mm10/VM15). Translation efficiencies were calculated by dividing CPM from libraries of ribosome-bound fragments by CPM from libraries of total input RNA after counting reads with HTSeq (Anders et al., 2015; only genes considered with minimum 25 counts per sample). Translation efficiencies were compared using t tests with significantly regulated genes being defined with an absolute fold change > 0.5 and a Benjamini-Hochberg corrected P value = Q < 0.1.

#### mRNA-Seq analysis

Samples were processed as described for input libraries in m^6^A/m-Seq data with differential gene expression analysis being performed with DESeq2 using the specified factorial models. For analysis of basal expression patterns as presented in Figure 5, only the subset of unstressed “Box” animals was used. Genes were considered differential with an absolute fold change > 0.5 and a Benjamini-Hochberg corrected P value = Q < 0.1.
**Gene expression analysis**
Statistics were performed on log2 normalized data using a 2x2 MANOVA in SPSS and were multiple testing-corrected by the Benjamini-Hochberg test (cut-off Q < 0.05) in R and a cut-off by effect size ($\eta^2 > 0.01$) and post hoc testing (Tukey HSD).

**Candidate m$^6$A/m-RIP-qPCR analysis**
RNA abundance levels were quantified from the input samples using the ddCT method normalizing to the average of all housekeeping genes. Immunoprecipitation efficiency for each biological sample was assessed using the measured abundance of spike-in per m$^6$A/m-RIP/IgG control sample. Because all conditions per sample were equally split at the beginning, % methylation or IgG signal was calculated as follows:

\[
\text{IP-efficiency corrected % methylated of total transcript} = \frac{\text{E}_{\text{CT}}(\text{IP or IgG}) - \text{E}_{\text{CT}}(\text{input})}{\text{E}_{\text{CT}}(\text{IP}) - \text{E}_{\text{CT}}(\text{input})} \times 1000
\]

Statistics were performed on log2 normalized data (RNA) or absolute values (m$^6$A/m) using a 2x2 MANOVA in SPSS with multiple testing performed using the Benjamini-Hochberg method (cut-off Q < 0.05) in R and a cut-off by effect size ($\eta^2 > 0.01$) and post hoc testing (Tukey HSD).

**Statistical analysis**
Statistical tests were performed using SPSS (IBM SPSS Statistics, Armonk, NY: IBM) and R (R Development Core Team, 2011) as indicated in Figure legends with n and statistical results indicated in Figure legends and Supplemental Tables. Plots were produced with R (R Development Core Team, 2011) ggplot2 (Wickham, 2009) with definition of presented measurements indicated in the Figure legends. For animal experiments, sample size was estimated a priori using G*Power (Faul et al., 2007) using $\alpha = 0.05$ and an experience-based $\beta$. Animals and samples within experiments were randomized using stratified randomization assisted by random number generation.

**DATA AND SOFTWARE AVAILABILITY**
All supporting data and code for this study are available from the corresponding author upon request. Sequencing data are deposited at GEO: GSE113801 with subseries GSE113781 (m$^6$A/m-Seq mouse cortex after acute stress), GSE113789 (Ribosome profiling Seq mouse cortex after acute stress), GSE113793 (m$^6$A/m-Seq of mouse adult cortex of Mettl3 cKO or Fto cKO mice), GSE113796 (mRNA-Seq of mouse Mettl3 cKO or Fto cKO mouse hippocampus after fear conditioning), GSE113798 (m$^6$A/m-Seq of human B-lymphocyte cell lines from healthy controls and major depressive disorder patients).